Bladder Cancer

Men appeared to have a higher risk for cancer than women at most shared anatomic sites, according to study results published in Cancer.

CHICAGO — Patients with bone metastases due to urothelial carcinoma had worse outcomes than those without bone metastasis, regardless of treatment or PD-L1 expression, according to a poster presentation at ASCO Annual Meeting.

Use of robot-assisted vs. open radical cystectomy led to a significantly increased number of days alive and out of the hospital among patients with nonmetastatic bladder cancer.

Donna Hansel, MD, PhD, has been named division head of pathology and laboratory medicine at The University of Texas MD Anderson Cancer Center.

Efforts to limit overuse of surveillance testing and treatment for low-risk nonmuscle-invasive bladder cancer are needed to alleviate increasing costs of care, results of a population-based cohort study suggested.

Elizabeth Plimack, MD, MS, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, has been appointed the center’s deputy director.

Among individuals with certain cancers, treatment with radiotherapy was associated with poorer long-term CV-specific survival compared with those who did not undergo radiotherapy, researchers reported.

SAN FRANCISCO — Addressing disparities in genitourinary cancers requires more research on changing risk factors and immediate actions aimed at prevention, Karen E. Knudsen, PhD, MBA, said during ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Neoadjuvant treatment with enfortumab vedotin demonstrated promising activity among cisplatin-ineligible patients with muscle-invasive bladder cancer, according to study results presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Lenvatinib plus pembrolizumab did not demonstrate a positive benefit-risk ratio compared with pembrolizumab and placebo as first-line therapy for certain patients with advanced urothelial carcinoma, study results showed.